159 related articles for article (PubMed ID: 24155829)
1. Evaluation of angiotensin II receptor blockers for drug formulary using objective scoring analytical tool.
Lim TM; Ibrahim MI
Pharm Pract (Granada); 2012 Jul; 10(3):136-42. PubMed ID: 24155829
[TBL] [Abstract][Full Text] [Related]
2. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension.
Israili ZH
J Hum Hypertens; 2000 Apr; 14 Suppl 1():S73-86. PubMed ID: 10854085
[TBL] [Abstract][Full Text] [Related]
3. Comparative effect of angiotensin II type I receptor blockers on serum uric acid in hypertensive patients with type 2 diabetes mellitus: a retrospective observational study.
Nishida Y; Takahashi Y; Susa N; Kanou N; Nakayama T; Asai S
Cardiovasc Diabetol; 2013 Nov; 12():159. PubMed ID: 24180232
[TBL] [Abstract][Full Text] [Related]
4. Cost effectiveness of angiotensin receptor blocker monotherapy in patients with hypertension in the Netherlands: a comparative analysis using clinical trial and drug utilization data.
Boersma C; Voors AA; Visser ST; de Jong-van den Berg LT; Postma MJ
Am J Cardiovasc Drugs; 2010; 10(1):49-54. PubMed ID: 20104934
[TBL] [Abstract][Full Text] [Related]
5. Use of multiattribute utility theory for formulary management in a health system.
Chung S; Kim S; Kim J; Sohn K
Am J Health Syst Pharm; 2010 Jan; 67(2):128-35. PubMed ID: 20065267
[TBL] [Abstract][Full Text] [Related]
6. Valsartan vs. other angiotensin II receptor blockers in the treatment of hypertension: a meta-analytical approach.
Nixon RM; Müller E; Lowy A; Falvey H
Int J Clin Pract; 2009 May; 63(5):766-75. PubMed ID: 19392925
[TBL] [Abstract][Full Text] [Related]
7. The effects of different angiotensin II type 1 receptor blockers on the regulation of the ACE-AngII-AT1 and ACE2-Ang(1-7)-Mas axes in pressure overload-induced cardiac remodeling in male mice.
Wang X; Ye Y; Gong H; Wu J; Yuan J; Wang S; Yin P; Ding Z; Kang L; Jiang Q; Zhang W; Li Y; Ge J; Zou Y
J Mol Cell Cardiol; 2016 Aug; 97():180-90. PubMed ID: 27210827
[TBL] [Abstract][Full Text] [Related]
8. Choice of angiotensin receptor blocker in moderate hypertension. A UK-based cost-benefit comparison of olmesartan- and candesartan-based regimens.
Belsey JD
J Med Econ; 2011; 14(5):553-61. PubMed ID: 21707445
[TBL] [Abstract][Full Text] [Related]
9. An application of a proposed framework for formulary listing in low-income countries: the case of Côte d'Ivoire.
Diaby V; Lachaine J
Appl Health Econ Health Policy; 2011 Nov; 9(6):389-402. PubMed ID: 22017499
[TBL] [Abstract][Full Text] [Related]
10. Economic evaluation of four angiotensin II receptor blockers in the treatment of hypertension.
Miller LA; Wade R; Dai D; Cziraky MJ; Ramaswamy K; Panjabi S
Curr Med Res Opin; 2010 Jun; 26(6):1307-20. PubMed ID: 20370377
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and duration of action of the four selective angiotensin II subtype 1 receptor blockers, losartan, candesartan, valsartan and telmisartan, in patients with essential hypertension determined by home blood pressure measurements.
Nishimura T; Hashimoto J; Ohkubo T; Kikuya M; Metoki H; Asayama K; Totsune K; Imai Y
Clin Exp Hypertens; 2005 Aug; 27(6):477-89. PubMed ID: 16081340
[TBL] [Abstract][Full Text] [Related]
12. Photosensitivity with Angiotensin II Receptor Blockers: A Retrospective Study Using Data from VigiBase(®).
Viola E; Coggiola Pittoni A; Drahos A; Moretti U; Conforti A
Drug Saf; 2015 Oct; 38(10):889-94. PubMed ID: 26187686
[TBL] [Abstract][Full Text] [Related]
13. Angiotensin II type 1 receptor blockers decrease kynurenic acid production in rat kidney in vitro.
Zakrocka I; Targowska-Duda KM; Wnorowski A; Kocki T; Jóźwiak K; Turski WA
Naunyn Schmiedebergs Arch Pharmacol; 2019 Feb; 392(2):209-217. PubMed ID: 30370429
[TBL] [Abstract][Full Text] [Related]
14. The place of ARBs in heart failure therapy: is aldosterone suppression the key?
Markan U; Pasupuleti S; Pollard CM; Perez A; Aukszi B; Lymperopoulos A
Ther Adv Cardiovasc Dis; 2019; 13():1753944719868134. PubMed ID: 31401939
[TBL] [Abstract][Full Text] [Related]
15. Antihypertensive effects of olmesartan compared with other angiotensin receptor blockers: a meta-analysis.
Wang L; Zhao JW; Liu B; Shi D; Zou Z; Shi XY
Am J Cardiovasc Drugs; 2012 Oct; 12(5):335-44. PubMed ID: 22920046
[TBL] [Abstract][Full Text] [Related]
16. Cost-benefit effectiveness of angiotensin-II receptor blockers in patients with uncomplicated hypertension: A comparative analysis.
Mazza A; Sacco AP; Townsend DM; Bregola G; Contatto E; Cappello I; Schiavon L; Ramazzina E; Rubello D
Biomed Pharmacother; 2017 Jun; 90():665-669. PubMed ID: 28415046
[TBL] [Abstract][Full Text] [Related]
17. Analysis of published economic evaluations of angiotensin receptor blockers.
Theodoratou D; Maniadakis N; Fragoulakis V; Stamouli E
Hellenic J Cardiol; 2009; 50(2):105-18. PubMed ID: 19329412
[TBL] [Abstract][Full Text] [Related]
18. Use of Angiotensin receptor blockers in cardiovascular protection: current evidence and future directions.
Munger MA
P T; 2011 Jan; 36(1):22-40. PubMed ID: 21386934
[TBL] [Abstract][Full Text] [Related]
19. Sympatho-inhibitory properties of various AT1 receptor antagonists.
Balt JC; Mathy MJ; Pfaffendorf M; van Zwieten PA
J Hypertens Suppl; 2002 Jun; 20(5):S3-11. PubMed ID: 12184061
[TBL] [Abstract][Full Text] [Related]
20. Olmesartan compared with other angiotensin II receptor antagonists: head-to-head trials.
Stumpe KO
Clin Ther; 2004; 26 Suppl A():A33-7. PubMed ID: 15291378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
